Nashville Biosciences

June 23, 2025

Low blood cell counts drive cancer in explosive blood disorder: study

The analysis of genetic sequencing data from more than 34,000 people over a 17-year period by researchers at VUMC was published in eClinicalMedicine.

By Bill Snyder

March 19, 2025

Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

The milestone creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program.

By VUMC News and Communications

January 5, 2024

The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK and Novo Nordisk

Bristol Myers Squibb, GSK and Novo Nordisk are the newest members of the Alliance for Genomic Discovery.

July 18, 2023

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer and Merck

Illumina Inc., in collaboration with Nashville Biosciences LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, have announced the five founding new members of the Alliance for Genomic Discovery.

By VUMC News and Communications

July 18, 2023

Alliance for Genomic Discovery FAQs

Here are frequently asked questions about Vanderbilt University Medical Center’s Alliance for Genomic Discovery.

By VUMC News and Communications

January 10, 2022

Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development

Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.

By Bill Snyder